uniQure BLA Filed as AMT-130 Shows 4-Year Huntington’s Functional Benefit
BLA FilingAMT-130Positive
AI Analysis
Summary
uniQure filed a BLA for AMT-130 in Huntington's disease based on 4-year functional benefit data from clinical trials. This regulatory milestone represents a key advancement for the gene therapy candidate.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
BLA filed with 4-year functional benefit data
Importance:8/10
Sentiment:
0.80
BLA_filingHuntington's_diseasegene_therapylong_term_data
Related Companies
Read the original article
Published by yahoo_finance on September 29, 2026 8:02 PM